Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lennar Corporation (LEN) vs TG Therapeutics Inc (TGTX) Price & Performance

Lennar CorporationTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Lennar Corporation vs TG Therapeutics Inc — how do they compare? Lennar Corporation trades at $85.78 (market cap $21.05B), while TG Therapeutics Inc trades at $49.69 (market cap $7.64B). The key difference: Lennar Corporation is far larger — about 2.8× TG Therapeutics Inc's market cap, and Lennar Corporation pays a 2.28% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

LENTGTX
Market Cap
$21.05B$7.64B
Sector
Consumer CyclicalHealth
52-Week High
$142.40$59.06
52-Week Low
$81.84$26.94
Enterprise Value
$24.93B$7.84B
Dividend Yield
2.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lennar Corporation

Lennar (LEN) trades at $85.82, showing modest daily gains of 0.26% amid mixed technical signals. The stock faces headwinds with three consecutive quarterly earnings misses and declining profitability margins, though valuation metrics remain attractive with P/E of 13.72 and P/B below 1.0. Recent news highlights institutional accumulation and dividend declarations while technical analysis indicates neutral momentum with key resistance at $88.

The outlook remains cautious as declining revenue and net income margins pressure near-term performance, though analyst consensus leans bullish with 46% buy ratings. Key risks include housing affordability challenges and elevated mortgage rates, while potential catalysts include operational efficiency improvements and market share gains in a competitive homebuilding sector.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

Returns comparison

Trailing returns across standard periods

About Lennar Corporation

Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.

Read more on LEN

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX